MicroRNA‑432‑5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer

Luo,Man; Hu,Zuowei; Kong,Yuefeng; Li,Lingyi

doi:10.3892/etm.2021.9732

MicroRNA‑432‑5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer

Authors:
- Man Luo
- Zuowei Hu
- Yuefeng Kong
- Lingyi Li
View Affiliations

Affiliations: Department of Oncology, Wuhan No. 1 Hospital, Wuhan, Hubei 430022, P.R. China, Department of Radiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: January 29, 2021 https://doi.org/10.3892/etm.2021.9732
Article Number: 301
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) play an important role in the occurrence and development of colorectal cancer (CRC). Evidence shows that miR‑432‑5p expression is decreased in various tumors and cancer cell lines. miR‑432‑5p can inhibit tumor invasion and metastasis, but its role in colorectal cancer is unclear. The present study demonstrated that miR‑432‑5p expression was decreased in colorectal cancer tissue and cell lines, and is negatively associated with invasion classification, lymph node metastasis and Tumor‑Node‑Metastasis stage. Kaplan‑Meier survival analysis showed that low miR‑432‑5p expression was associated with a poor survival rate in patients with CRC. In addition, SW480 and HT‑29 cells transfected with miR‑432‑5p mimics had decreased migration and invasion abilities, whereas miR‑432‑5p inhibitors had the opposite effect. The expression of C‑X‑C motif chemokine ligand 5 (CXCL5), a direct target of miR‑432‑5p, was negatively associated with miR‑432‑5p expression. When CXCL5 was introduced into miR‑432‑5p mimic‑transfected SW480 and HT‑29 cells, miR‑432‑5p‑mediated inhibition of CRC migration and invasion was reversed. Thus, the present results suggest that miR‑432‑5p can inhibit the migration and invasion of CRC cells by targeting CXCL5.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.PubMed/NCBI View Article : Google Scholar
3	Grady WM and Markowitz SD: The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci. 60:762–772. 2015.PubMed/NCBI View Article : Google Scholar
4	Vishnoi A and Rani S: MiRNA biogenesis and regulation of diseases: An overview. Methods Mol Bio. 1509:1–10. 2017.PubMed/NCBI View Article : Google Scholar
5	Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C and Irimie A: The impact of miRNA in colorectal cancer progression and its liver metastases. Int J Mol Sci. 19(3711)2018.PubMed/NCBI View Article : Google Scholar
6	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014.PubMed/NCBI View Article : Google Scholar
7	Ak S, Tunca B, Tezcan G, Cecener G, Egeli U, Yilmazlar T, Ozturk E and Yerci O: MicroRNA expression patterns of tumors in early-onset colorectal cancer patients. J Surg Res. 191:113–122. 2014.PubMed/NCBI View Article : Google Scholar
8	Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Deve Ther. 8:293–314. 2014.PubMed/NCBI View Article : Google Scholar
9	Yao T, Rao Q, Liu L, Zheng C, Xie Q, Liang J and Lin Z: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol J. 10(175)2013.PubMed/NCBI View Article : Google Scholar
10	Wang S, Gao B, Yang H, Liu X, Wu X and Wang W: MicroRNA-432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion. Oncol Lett. 18:1475–1482. 2019.PubMed/NCBI View Article : Google Scholar
11	D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J and Fusco A: Altered microRNA expression profile in human pituitary GH adenomas: Down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab. 97:E1128–E1138. 2012.PubMed/NCBI View Article : Google Scholar
12	Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC, Zhang T, Li Y and Wang GY: Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation. Oncotarget. 6:7866–7879. 2015.PubMed/NCBI View Article : Google Scholar
13	Lv D, Zhen Z and Huang D: MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1. Exp Ther Med. 17:919–926. 2019.PubMed/NCBI View Article : Google Scholar
14	Chen L, Kong G, Zhang C, Dong H, Yang C, Song G, Guo C, Wang L and Yu H: MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma. Oncotarget. 7:20041–20053. 2016.PubMed/NCBI View Article : Google Scholar
15	Wang T, Du M, Zhang W, Bai H, Yin L, Chen W, He X and Chen Q: MicroRNA-432 suppresses invasion and migration via E2F3 in nasopharyngeal carcinoma. Onco Targets Ther. 12:11271–11280. 2019.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15(38)2015.PubMed/NCBI View Article : Google Scholar
18	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015.PubMed/NCBI View Article : Google Scholar
19	Eashita D and Nitai PB: MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. FEBS Lett. 588:1706–1714. 2014.PubMed/NCBI View Article : Google Scholar
20	Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, et al: microRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 123:2703–2718. 2013.PubMed/NCBI View Article : Google Scholar
21	Zlotnik A and Yoshie O: The chemokine superfamily revisited. Immunity. 36:705–716. 2012.PubMed/NCBI View Article : Google Scholar
22	Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa SM, You Q and Miao L: CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond). 40:69–80. 2020.PubMed/NCBI View Article : Google Scholar
23	Hu B, Fan H, Lv X, Chen S and Shao Z: Prognostic significance of CXCL5 expression in cancer patients: A meta-analysis. Cancer Cell Int. 18(68)2018.PubMed/NCBI View Article : Google Scholar
24	Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer. 16(70)2017.PubMed/NCBI View Article : Google Scholar
25	Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, Zheng MH, Zhao JK and Lu AG: CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Cell Death Dis. 10(178)2019.PubMed/NCBI View Article : Google Scholar
26	Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res. 14:2276–2284. 2008.PubMed/NCBI View Article : Google Scholar
27	Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M: CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 48:2244–2251. 2012.PubMed/NCBI View Article : Google Scholar